If you would like to be first in line to receive our press releases, please send an email that includes your full name, affiliation, and contact information.
Contact us:
press@healthgap.org
Our policy experts are available for interviews. Please contact us for more information about setting up a meeting.
July 23, 2024|Access to MedicinesActivists at AIDS2024 Demand: Break Gilead’s Lenacapavir Monopoly Gilead’s Price 100,000% Higher than Target Generic Price for 100% Effective Prevention Shot(Munich) Today at AIDS 2024, a coalition of activists called for immediate global action to break Gilead’s monopoly on lenacapavir, in response to new data showing that generic lenacapavir can be produced at a price one thousand times less than…
May 20, 2024|Health JusticeLGBTQ+, HIV Activists Demand U.S. Accountability on Human Rights in Kenya Ahead of President Ruto’s State VisitWhile LGBTQ+ Persecution Increases in Kenya, Ruto Seeks Major Deals with Coca-Cola and other U.S. Companies Lauded for Pro-LGBTQ+ Workplace Policies (Washington, D.C.) Human rights organizations called on the Biden administration to honor his promise to advance the rights…
March 13, 2024|Funding the FightPresident Biden’s Global HIV/AIDS Budget Fails to Meet the MomentWith Just 5 Years Left to Defeat AIDS as a Public Health Threat, Flat Funding Doesn’t do Enough to Save the Lives of People Living with HIV President Biden released his Fiscal Year 2025 (FY25) budget request on Monday, detailing…
February 6, 2024|Access to MedicinesStatement from Naïké Ledan, Health GAP Director of International Policy & Advocacy, on Colombia’s Historic Compulsory License for DolutegravirStatement from Naïké Ledan, Health GAP Director of International Policy & Advocacy, on Colombia’s Historic Compulsory License for Dolutegravir "Dolutegravir (DTG) is a lifesaving HIV treatment that can improve and extend the lives of people with HIV. DTG-based regimens are…
